Mattsson et al [34], [35] showed lower SgcII levels in a mixed MS population compared to healthy controls (HC) and Alzheimer’s Disease (AD) subjects, and a significant correlation between these levels and AβPP-derived peptides, suggesting that it might be involved in the cerebral neurodegeneration connected to amyloid metabolism [35]. This evidence concerns the gene APP and early-onset autosomal dominant Alzheimer disease.